title: [Repeated occlusion of the intraperitoneal access port for intraperitoneal chemotherapy in a patient with gastric cancer with peritoneal dissemination].
abstract: A phase III clinical trial to evaluate the efficacy of combination chemotherapy with intraperitoneal administration of paclitaxel for gastric cancer with peritoneal metastasis has been ongoing in Japan. A male patient in his 50s who was diagnosed as having advanced gastric cancer with peritoneal metastasis was enrolled in this trial. The patient was assigned to receive a regimen of intravenous and intraperitoneal paclitaxel combined with S-1. Although an intraperitoneal access port had been implanted to provide access to the peritoneal cavity, tube obstruction occurred twice. Laparoscopic examination revealed that the tube in the abdominal cavity had been totally covered with the great omentum. Therefore, the intraperitoneal regimen was discontinued. Although intraperitoneal chemotherapy for the treatment of peritoneal dissemination in gastric cancer is promising, precaution should be taken to avoid tube obstruction, which is a complication of the intraperitoneal tube placement.
authors.affiliation: Dept. of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases.
authors.forename: Kazuki
authors.initials: K
authors.lastname: Sasaki
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Fujiwara
authors.forename: Kentaro
authors.initials: K
authors.lastname: Kishi
authors.forename: Masaaki
authors.initials: M
authors.lastname: Motoori
authors.forename: Keijiro
authors.initials: K
authors.lastname: Sugimura
authors.forename: Norikatsu
authors.initials: N
authors.lastname: Miyoshi
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Akita
authors.forename: Kunihito
authors.initials: K
authors.lastname: Gotoh
authors.forename: Hidenori
authors.initials: H
authors.lastname: Takahashi
authors.forename: Shigeru
authors.initials: S
authors.lastname: Marubashi
authors.forename: Shingo
authors.initials: S
authors.lastname: Noura
authors.forename: Masayuki
authors.initials: M
authors.lastname: Ohue
authors.forename: Masahiko
authors.initials: M
authors.lastname: Yano
authors.forename: Masato
authors.initials: M
authors.lastname: Sakon
authors.forename: Hironori
authors.initials: H
authors.lastname: Ishigami
authors.forename: Joji
authors.initials: J
authors.lastname: Kitayama
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D010529:Peritoneal Cavity / Q000473:pathology*; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage; D062666:Vascular Access Devices
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel